We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Corneal epithelial toxicity induced by belantamab mafodotin.
- Authors
Patel, Savan V.; Joshi, Nisarg; Thareja, Tarika; Jhanji, Vishal
- Abstract
Belantamab mafodotin (belamaf) is a first-in-class antibody-drug conjugate (ADC) therapeutic approved for relapsed/refractory multiple myeloma.1 We report the eye disease in two participants in the GSK 213304 Expanded Access programme for belamaf, who had failed at least three prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent and developed keratopathy after administration of belamaf. (A-C) Patient 1 right eye and (D) Patient 2 left eye. (A) Patient 1 left eye and (B) Patient 1 right eye gl Patient 2 was a 72-year-old man with Stage III IgA Lambda MM.
- Publication
Clinical & Experimental Ophthalmology, 2021, Vol 49, Issue 9, p1113
- ISSN
1442-6404
- Publication type
Academic Journal
- DOI
10.1111/ceo.13995